Sana biotechnology reports fourth quarter and full year 2023 financial results and business updates

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, b-cell mediated autoimmune diseases, and type 1 diabetes

SANA Ratings Summary

SANA Quant Ranking